Low-Dose Cannabidiol
Phase 3Small molecule
Low-Dose Cannabidiol is one of 39 small molecule programs targeting Generalized Anxiety Disorder. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Generalized Anxiety Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaPhase 3
Viibryd
AbbViePhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
PD 0360324
PfizerPhase 3
Risperdal
WWim Janssens
Phase 3
Effexor
WWyeth-Lederle Vaccines
Phase 3
Quetiapine XR
AstraZenecaPhase 3
Lu AF95245
LundbeckPhase 3
Venlafaxine XR
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Endari
EEmmaus Medical, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Low-Dose Cannabidiol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- WWayne State University